US2007149474A1PendingUtilityA1

Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of chlamydia

64
Assignee: UNIV AUBURNPriority: Dec 15, 2000Filed: Dec 27, 2006Published: Jun 28, 2007
Est. expiryDec 15, 2020(expired)· nominal 20-yr term from priority
Inventors:Stephen JohnstonKatherine Stemke-HaleKathryn F. SykesBernhard Kaltenboeck
A61K 2039/53A61P 31/04A61P 37/04A61K 39/118
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The instant invention relates to antigens and nucleic acids encoding such antigens obtainable by screening a Chlamydia genome. In more specific aspects, the invention relates to methods of isolating such antigens and nucleic acids and to methods of using such isolated antigens for producing immune responses. The ability of an antigen to produce an immune response may be employed in vaccination or antibody preparation techniques.

Claims

exact text as granted — not AI-modified
1 . A vaccine comprising: 
 (a) a pharmaceutically acceptable carrier, and    (b) at least one polynucleotide having a  Chlamydia  sequence.    
     
     
         2 . The vaccine of  claim 1 , wherein the at least one polynucleotide has a  Chlamydia psittaci  sequence.  
     
     
         3 . The vaccine of  claim 1 , wherein the at least one polynucleotide has a  Chlamydia pneumoniae  sequence.  
     
     
         4 . The vaccine of  claim 1 , wherein the at least one polynucleotide has a sequence isolated from a  Chlamydia psittaci  genomic DNA expression library.  
     
     
         5 . The vaccine of  claim 4 , wherein the at least one polynucleotide has a sequence isolated from a  Chlamydia psittaci  genomic DNA expression library.  
     
     
         6 . The vaccine of  claim 1 , wherein the at least one polynucleotide has a sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, or fragment thereof.  
     
     
         7 . The vaccine of  claim 6 , wherein the at least one polynucleiotide has a sequence of SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, or SEQ ID NO:26, or fragment thereof.  
     
     
         8 . The vaccine of  claim 6 , wherein the at least one polynucleotide has a sequence of SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:20, or SEQ ID NO:24, or fragment thereof.  
     
     
         9 . The vaccine of  claim 1 , wherein at least one polynucleotide has a sequence of SEQ ID NO:62, SEQ ID NO:64, SEQ ID NO:66, or SEQ ID NO:68 or fragment thereof.  
     
     
         10 . The vaccine of  claim 1 , comprising a polynucleotide encoding an antigen having a sequence of SEQ ID NO:7, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, or SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, or SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:61, or an antigenic fragment thereof.  
     
     
         11 . The vaccine of  claim 1 , comprising a polynucleotide encoding an antigen having a sequence of SEQ ID NO:63, SEQ ID NO:65, SEQ ID NO:67, or SEQ ID NO:69, or an antigenic fragment thereof.  
     
     
         12 . The vaccine of  claim 1 , wherein the polynucleotide is comprised in generic immunization vector.  
     
     
         13 . The vaccine of  claim 12 , wherein the vector comprises a gene encoding a mouse ubiquitin fusion polypeptide.  
     
     
         14 . The vaccine of  claim 12 , wherein the vector comprises a promoter operable in eukaryotic cells.  
     
     
         15 . The vaccine of  claim 14 , wherein the promoter is a CMV promoter.  
     
     
         16 . The vaccine of  claim 1 , wherein the polynucleotide is cloned into a viral expression vector.  
     
     
         17 . The vaccine of  claim 16 , wherein the viral expression is selected form the group consisting of adenvirus, adeno-associated virus, retrovirus and herpes-simplex virus.  
     
     
         18 . The vaccine of  claim 1 , comprising at least a first polynucleotide having a  Chlamydia psittaci  sequence and a second polynucleotide having a sequence, wherein the first polynucleotide and the second polynucleotide have different sequences.  
     
     
         19 . The vaccine of  claim 6 , wherein the first polynucleotide has a sequence of SEQ ID NO: 50.  
     
     
         20 . A vaccine comprising: 
 (a) a pharmaceutically acceptable carrier; and    (b) at least one  Chlamydia  antigen.    
     
     
         21 . The vaccine of  claim 20 , wherein the at least one  Chlamydia  antigen has a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO. 15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:61, or an antigenic fragment thereof.  
     
     
         22 . The vaccine of  claim 20 , where the at least one  Chlamydia  antigen has a sequence of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO. 15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, or SEQ ID NO:27, or an antigenic fragment thereof.  
     
     
         23 . The vaccine of  claim 20 , wherein the at least one  Chlamydia  antigen has a sequence of SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO.15, SEQ ID NO:21, or SEQ ID NO:25, or an antigenic fragment thereof.  
     
     
         24 . The vaccine of  claim 20 , wherein the at least one  Chlamydia  antigen has a sequence of SEQ ID NO:63, SEQ ID NO:65, SEG ID NO:67, or SEQ ID NO:69, or an antigenic fragment thereof.  
     
     
         25 - 73 . (canceled)

Join the waitlist — get patent alerts

Track US2007149474A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.